Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement

Benjamin Lardinois; Michaël Hardy; Isabelle Michaux; Geoffrey Horlait; Thomas Rotens; Hugues Jacqmin; Sarah Lessire; Pierre Bulpa; Alain Dive; François Mullier

doi:10.3390/jcm11051338

Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement

J Clin Med. 2022 Feb 28;11(5):1338. doi: 10.3390/jcm11051338.

Authors

Benjamin Lardinois¹, Michaël Hardy^{1

2

3}, Isabelle Michaux⁴, Geoffrey Horlait⁴, Thomas Rotens⁴, Hugues Jacqmin¹, Sarah Lessire^{2

3}, Pierre Bulpa⁴, Alain Dive⁴, François Mullier^{1

3}

Affiliations

¹ Hematology Laboratory, CHU UCL Namur, Université Catholique de Louvain, 5530 Yvoir, Belgium.
² Anesthesiology Department, CHU UCL Namur, Université Catholique de Louvain, 5530 Yvoir, Belgium.
³ Namur Thrombosis and Hemostasis Center (NTHC), CHU UCL Namur, Université Catholique de Louvain, 5530 Yvoir, Belgium.
⁴ Department of Intensive Care, CHU UCL Namur, Université Catholique de Louvain, 5530 Yvoir, Belgium.

Abstract

Continuous intravenous unfractionated heparin (UFH) is administered routinely in the intensive care unit (ICU) for the anticoagulation of patients, and monitoring is performed by the activated partial thromboplastin time (APTT) or anti-Xa activity. However, these strategies are associated with potentially large time intervals before dose adjustments, which could be detrimental to the patient. The aim of the study was to compare a point-of-care (POCT) version of the APTT to (i) laboratory-based APTT and (ii) measurements of anti-Xa activity in terms of correlation, agreement and turnaround time (TAT). Thirty-five ICU patients requiring UFH therapy were prospectively included and followed longitudinally for a maximum duration of 15 days. UFH was administered according to a local adaptation of Raschke and Amanzadeh’s aPTT nomograms. Simultaneous measurements of POCT-APTT (CoaguCheck® aPTT Test, Roche Diagnostics) on a drop of fresh whole blood, laboratory-based APTT (C.K. Prest®, Stago) and anti-Xa activity (STA®Liquid anti-Xa, Stago) were systematically performed two to six times a day. Antithrombin, C-reactive protein, fibrinogen, factor VIII and lupus anticoagulant were measured. The time tracking of sampling and analysis was recorded. The overall correlation between POCT-APTT and laboratory APTT (n = 795 pairs) was strongly positive (rs = 0.77, p < 0.0001), and between POCT-APTT and anti-Xa activity (n = 729 pairs) was weakly positive (rs = 0.46, p < 0.0001). Inter-method agreement (Cohen’s kappa (k)) between POCT and laboratory APTT was 0.27, and between POCT and anti-Xa activity was 0.30. The median TATs from sample collection to the lab delivery of results for lab-APTT and anti-Xa were 50.9 min (interquartile range (IQR), 38.4−69.1) and 66.3 min (IQR, 49.0−91.8), respectively, while the POCT delivered results in less than 5 min (p < 0.0001). Although the use of the POCT-APTT device significantly reduced the time to results, the results obtained were poorly consistent with those obtained by lab-APTT or anti-Xa activity, and therefore it should not be used with the nomograms developed for lab-APTT.

Keywords: APTT; POCT; anti-Xa; heparin; monitoring; unfractionated heparin.